Population Genomic Screening: Assessing Clinical Yield and Economic Impact

Population genomic screening is rapidly transitioning from specialized clinical practice to broader public health initiatives. This approach aims to identify individuals with monogenic risks for medically actionable conditions who might otherwise remain undetected. A recent large-scale study explores the real-world yield of these screenings and their subsequent impact on healthcare utilization and financial costs.

Yield of Actionable Genetic Findings

The study evaluated 50,063 individuals using genomic panels covering up to 167 genes. Researchers identified pathogenic or likely pathogenic variants in 8.6% of participants. This high yield suggests that a significant portion of the general population carries genetic risks that warrant clinical attention. Consequently, population genomic screening serves as a vital tool for early disease detection and risk mitigation.

Impact on Healthcare Utilization and Costs

Healthcare providers often express concern that population-wide testing might lead to a surge in unnecessary medical utilization. However, the data indicates that while relevant healthcare visits increased for those with positive results, the overall economic impact was modest. Specifically, the median cost of all-cause healthcare only rose from $215 to $340 post-test for participants with positive results. In contrast, those with negative results saw no significant change in costs. These findings suggest that screening prompts targeted, necessary care without overwhelming the healthcare system's resources.

Implementing Population Genomic Screening in Practice

For clinicians, the integration of genomic data into routine care allows for personalized prevention strategies. By identifying risks for conditions such as Lynch syndrome or hereditary cancers, physicians can implement surveillance protocols early. Furthermore, the manageable cost profile of these screenings supports their adoption in diverse clinical settings, including primary care and multispecialty clinics. Ultimately, this proactive model shift may improve long-term outcomes while maintaining economic sustainability.

FAQs

What is the clinical yield of population genomic screening?

In large-scale real-world studies, approximately 8.6% of individuals screened were found to have pathogenic or likely pathogenic variants associated with monogenic disorders.

Does genetic screening significantly increase healthcare spending?

While there is a small increase in healthcare utilization for individuals who test positive, research suggests the overall median cost increase is modest and does not significantly burden the healthcare system.

Which conditions are typically covered in genomic screening panels?

Panels often include genes associated with medically actionable conditions, such as those on the ACMG secondary findings list, including hereditary cancers and cardiovascular disorders.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.

References

• Ekstein T et al. Genetic findings and healthcare utilization among individuals undergoing population genomic screening for actionable hereditary disorders. Genet Med. 2026 May 19. doi: undefined. PMID: 42153369.


• Schwartz MLB, et al. Genetics Visit Uptake Among Individuals Receiving Clinically Actionable Genomic Screening Results. JAMA Netw Open. 2024;7(3):e242388.


• Mighton C, et al. From the patient to the population: Use of genomics for population screening. Front Genet. 2022;13:893832.